Navigating the Microbial Basis of Inflammatory Bowel Diseases: Seeing the Light at the End of the Tunnel

키워드

참고문헌 (40)

1. Loftus EV Jr, "Clinical epidemiology of inflammatory bowel disease:incidence, prevalence, and environmental influences", Gastroenterology, 126, pp.1504~1517 (2004)
2. Lee YK, "Has the microbiota played a critical role in the evolution of the adaptive immune system?", Science, 330, pp.1768~1773 (2010)
3. Devkota S, "Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-", -mice, 2012, pp.487, 104~108
4. Dalal SR, "The microbial basis of inflammatory bowel diseases", J Clin Invest, 124, pp.4190~4196 (2014)
5. Arrieta MC, "The intestinal microbiome in early life: health and disease", Front Immunol, 5, pp.427~ (2014)
6. Human Microbiome Project Consortium, "Structure, function and diversity of the healthy human microbiome", Nature, 486, pp.207~214 (2012)
7. Dominguez-Bello MG, "Development of the human gastrointestinal microbiota and insights from highthroughput sequencing", Gastroenterology, 140, pp.1713~1719 (2011)
8. Morgan XC, "Biodiversity and functional genomics in the human microbiome", Trends Genet, 29, pp.51~58 (2013)
9. Hookman P, "Clostridium difficile associated infection, diarrhea and colitis", World J Gastroenterol, 15, pp.1554~1580 (2009)
10. Theriot CM, "Microbial and metabolic interactions between the gastrointestinal tract and Clostridium difficile infection", Gut Microbes, 5, pp.86~95 (2014)
11. Wu HJ, "The role of gut microbiota in immune homeostasis and autoimmunity", Gut Microbes, 3, pp.4~14 (2012)
12. Johnson CC, "Antibiotic exposure in early infancy and risk for childhood atopy", J Allergy Clin Immunol, 115, pp.1218~1224 (2005)
13. Kilkkinen A, "Use of antimicrobials and risk of type 1 diabetes in a population-based mother-child cohort", Diabetologia, 49, pp.66~70 (2006)
14. Arvonen M, "Repeated exposure to antibiotics in infancy: a predisposing factor for juvenile idiopathic arthritis or a sign of this group’s greater susceptibility to infections?", J Rheumatol, 42, pp.521~526 (2015)
15. Virta L, "Association of repeated exposure to antibiotics with the development of pediatric Crohn’s disease: a nationwide, register-based Finnish case-control study", Am J Epidemiol, 175, pp.775~784 (2012)
16. Shaw SY, "Association between the use of antibiotics and new diagnoses of Crohn’s disease and ulcerative colitis", Am J Gastroenterol, 106, pp.2133~2142 (2011)
17. Hicks LA, "U.S. outpatient antibiotic prescribing, 2010", N Engl J Med, 368, pp.1461~1462 (2013)
18. McCaig LF, "Antimicrobial drug prescription in ambulatory care settings, United States, 1992-2000", Emerg Infect Dis, 9, pp.432~437 (2003)
19. Nash DR, "Antibiotic prescribing by primary care physicians for children with upper respiratory tract infections", Arch Pediatr Adolesc Med, 156, pp.1114~1119 (2002)
20. Dethlefsen L, "Incomplete recovery and individualized responses of the human distal gut microbiota to repeated antibiotic perturbation", Proc Natl Acad Sci U S A, 108(1), pp.4554~4561 (2011)
21. Correale J, "Association between parasite infection and immune responses in multiple sclerosis", Ann Neurol, 61, pp.97~108 (2007)
22. Büning J, "Helminths as governors of inflammatory bowel disease", Gut, 57, pp.1182~1183 (2008)
23. Elliott DE, "Helminths as governors of immune-mediated inflammation", Int J Parasitol, 37, pp.457~464 (2007)
24. Weinstock JV, "Role of helminths in regulating mucosal inflammation", Springer Semin Immunopathol, 27, pp.249~271 (2005)
25. Jostins L, "Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease", Nature, 491, pp.119~124 (2012)
26. Liu JZ, "Association analyses identify 38 susceptibility loci for inflammatory bowel disease and highlight shared genetic risk across populations", Nat Genet, 47, pp.979~986 (2015)
27. D’Haens GR, "Early lesions of recurrent Crohn’s disease caused by infusion of intestinal contents in excluded ileum", Gastroenterology, 114, pp.262~267 (1998)
28. Macpherson A, "Mucosal antibodies in inflammatory bowel disease are directed against intestinal bacteria", Gut, 38, pp.365~375 (1996)
29. Sokol H, "The intestinal microbiota in inflammatory bowel diseases: time to connect with the host", Curr Opin Gastroenterol, 26, pp.327~331 (2010)
30. Sokol H, "Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients", Proc Natl Acad Sci U S A, 105, pp.16731~16736 (2008)
31. Varela E, "Colonisation by Faecalibacterium prausnitzii and maintenance of clinical remission in patients with ulcerative colitis", Aliment Pharmacol Ther, 38, pp.151~161 (2013)
32. Roediger WE, "Colonic sulfide in pathogenesis and treatment of ulcerative colitis", Dig Dis Sci, 42, pp.1571~1579 (1997)
33. Gevers D, "The treatment-naive microbiome in new-onset Crohn’s disease", Cell Host Microbe, 15, pp.382~392 (2014)
34. Morgan XC, "Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment", Genome Biol, 13, pp.R79~ (2012)
35. Morgan XC, "Associations between host gene expression, the mucosal microbiome, and clinical outcome in the pelvic pouch of patients with inflammatory bowel disease", Genome Biol, 16, pp.67~ (2015)
36. Atarashi K, "Treg induction by a rationally selected mixture of Clostridia strains from the human microbiota", Nature, 500, pp.232~236 (2013)
37. Bennet JD, "Treatment of ulcerative colitis by implantation of normal colonic flora", Lancet, 1, pp.164~ (1989)
38. Colman RJ, "Fecal microbiota transplantation as therapy for inflammatory bowel disease: a systematic review and metaanalysis", J Crohns Colitis, 8, pp.1569~1581 (2014)
39. Moayyedi P, "Fecal microbiota transplantation induces remission in patients with active ulcerative colitis in a randomized controlled trial", Gastroenterology, 149(e6), pp.102~109 (2015)
40. Rossen NG, "Findings from a randomized controlled trial of fecal transplantation for patients with ulcerative colitis", Gastroenterology, 149(e4), pp.110~118 (2015)

관련 논문AI추천